Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

ABSTRACT:

Background

Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear.

Methods

We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial. Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total. HIV-1 testing was performed every 4 weeks. The VRC01 80% inhibitory concentration (IC₈₀) of acquired isolates was measured with the TZM-bl assay.

Results

Adverse events were similar in number and

SUBMITTER: Corey L 

PROVIDER: S-EPMC8189692 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature